Transplantation with GXHPC1 for Liver Cirrhosis: Phase 1 Trial (2019)
GXHPC1® 於人體臨床試驗第一期結果顯示，擴增之自體脂肪間質幹細胞不僅無不良反應，還有助於改善肝硬化患者的肝功能、METAVIR 分數、Child–Pugh 分數、與 MELD 分數，顯示其臨床應用的安全與有效性。
Huang, K. C., Chuang, M. H., Lin, Z. S., Lin, Y. C., Chen, C. H., Chang, C. L., Huang, P. C., Syu, W. S., Chiou, T. W., Hong, Z. H., Tsai, Y. C., Harn, H. J., Lin, P. C., & Lin, S. Z. (2019). Transplantation with GXHPC1 for Liver Cirrhosis: Phase 1 Trial. Cell transplantation, 28(1_suppl), 100S–111S.
Mesenchymal stem cells facilitate recovery from chemically induced liver damage and decrease liver fibrosis (2009)
經由肝門靜脈注射人類骨髓間質幹細胞（hBMMSCs）可顯著減少大鼠肝纖維化，並促進肝損傷的恢復，為肝硬化治療提供潛在的治療方案。
Chang, Y. J., Liu, J. W., Lin, P. C., Sun, L. Y., Peng, C. W., Luo, G. H., Chen, T. M., Lee, R. P., Lin, S. Z., Harn, H. J., & Chiou, T. W. (2009). Mesenchymal stem cells facilitate recovery from chemically induced liver damage and decrease liver fibrosis. Life sciences, 85(13-14), 517–525.
Commercial Production of Autologous Stem Cells and Their Therapeutic Potential for Liver Cirrhosis (2017)
本研究透過國璽的製程於4代內擴增幹細胞 1,000 倍，約 1 億顆的人類脂肪幹細胞 (hADSCs)，並測試培養後 hADSCs 的型態、生物特徵、與活性等。此外，在肝硬化動物模型中，培養後的幹細胞植入顯示出穩定的治療效果與高存活率，更重要的是，植入長期觀察並未發生腫瘤風險，顯示國璽幹細胞生產的品質與臨床應用潛力。
Lin, Y. C., Harn, H. J., Lin, P. C., Chuang, M. H., Chen, C. H., Lin, S. Z., & Chiou, T. W. (2017). Commercial Production of Autologous Stem Cells and Their Therapeutic Potential for Liver Cirrhosis. Cell transplantation, 26(3), 449–460.
A Proposed Novel Stem Cell Therapy Protocol for Liver Cirrhosis (2015)
在肝硬化治療中，自體脂肪間質幹細胞 (ADSCs) 具備免疫優勢，具潛力成為替代肝臟移植的創新療法。本研究提案自體 ADSCs 應用於肝硬化的安全性和療效，為臨床上肝硬化治療提供一項新選擇。
Lin, P. C., Chiou, T. W., Lin, Z. S., Huang, K. C., Lin, Y. C., Huang, P. C., Syu, W. S., Harn, H. J., & Lin, S. Z. (2015). A proposed novel stem cell therapy protocol for liver cirrhosis. Cell transplantation, 24(3), 533–540.
Adipose-Derived Stem Cells Can Abrogate Chemical-Induced Liver Fibrosis and Facilitate Recovery of Liver Function (2012)
脂肪間質幹細胞 (hADSCs) 在大鼠肝臟損傷模型中於一天內促進肝損傷的恢復，顯著改善肝臟纖維化，研究結果顯示移植後的幹細胞數量與纖維化減少程度呈現正相關。此研究結果顯示間質幹細胞治療對於肝硬化的臨床應用潛力。
Harn, H. J., Lin, S. Z., Hung, S. H., Subeq, Y. M., Li, Y. S., Syu, W. S., Ding, D. C., Lee, R. P., Hsieh, D. K., Lin, P. C., & Chiou, T. W. (2012). Adipose-derived stem cells can abrogate chemical-induced liver fibrosis and facilitate recovery of liver function. Cell transplantation, 21(12), 2753–2764.